← Leaderboards
Robert Warren Gould
Vanderbilt University
$4,108,932
Attributed
$9,718,297
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.8M · FY2017–24$10M$7.5M$5M$2.5M$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,718,297 · 5
By mechanism
R01$6,445,203 · 1
U43$1,968,844 · 1
R00$746,998 · 1
R21$373,788 · 1
K99$183,464 · 1
Top collaborators
- Reto Andreas Gadient2 shared
- Douglas J Sheffler2 shared
- Nicholas David Cosford1 shared
- Gonul Velicelebi1 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Craig Lindsley$38,671,033
- Jerri Michelle Rook$4,711,471
- P Jeffrey Conn$37,782,937
- Max E Joffe$3,703,746
- Jing Zhang$29,552,230
Others in their field
Other Emerging Leaders on “Rattus”
- John Damon Chodera · Sloan-Kettering Inst Can Research$33,543,727
- Xinhua Li · Nano Terra, Inc.$23,579,188
- Barney Sparrow · Battelle Memorial Institu$16,547,191
- Vera Hoffman · Reveal Pharma$14,477,163
- Nikej Shah · Nirsum Laboratories, Inc.$12,506,430
- Gonul Velicelebi · Sanford Burnham Prebys Medical Discovery Institute$8,970,452
Research focus
RattusIn VivoGlutamatesSleepSleep DisturbancesPrefrontal CortexAttenuatedRelapseReportingMetabotropic Glutamate ReceptorsSelf AdministrationSignal TransductionPharmacological TreatmentPreclinical StudyResearch PersonnelDrug UsageElectroencephalographyBehaviorAbstinenceCuesRodentAffectMediatingDose
Grant awards (9)
Preclinical validation of mGlu2 PAMs in alcohol use disorder$994,906
U43 · FY2024 · AA
Preclinical validation of mGlu2 PAMs in alcohol use disorder$973,938
U43 · FY2023 · AA
Characterization, optimization, and development of dual mGlu2/3 positive allosteric modulators for opioid use disorder$6,445,203
R01 · FY2022 · DA
Estrogen depletion as a risk factor for Neuropsychiatric Symptoms associated with aging$373,788
R21 · FY2022 · AG · contact PI
Partial mGlu5 Negative Allosteric Modulators to Prevent Relapse to Cocaine Abuse$248,999
R00 · FY2021 · DA · contact PI
Partial mGlu5 Negative Allosteric Modulators to Prevent Relapse to Cocaine Abuse$248,999
R00 · FY2020 · DA · contact PI
Partial mGlu5 Negative Allosteric Modulators to Prevent Relapse to Cocaine Abuse$249,000
R00 · FY2019 · DA · contact PI
Partial mGlu5 Negative Allosteric Modulators to Prevent Relapse to Cocaine Abuse$91,732
K99 · FY2018 · DA · contact PI
Partial mGlu5 Negative Allosteric Modulators to Prevent Relapse to Cocaine Abuse$91,732
K99 · FY2017 · DA · contact PI